Investigating how LINE-1 expression affects the immune response in ovarian cancer
Immunological consequences of LINE-1 expression in cancer
This study is looking at how a specific part of our DNA, called LINE-1, affects the immune system in women with high-grade serous ovarian cancer, hoping to find new ways to improve treatments and help the body fight the cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11052654 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of LINE-1, a type of transposable element, in ovarian cancer, particularly its impact on the immune system. The study examines how LINE-1 expression changes during the progression of high-grade serous ovarian cancer, which is characterized by mutations in the TP53 gene. By analyzing the relationship between LINE-1 activation and immune signaling, the research aims to uncover new therapeutic targets that could enhance anti-tumor responses. Patients may benefit from insights that could lead to novel treatments for ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with high-grade serous ovarian cancer, particularly those with TP53 mutations.
Not a fit: Patients with other types of cancer or those without TP53 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve survival rates for ovarian cancer patients.
How similar studies have performed: Previous studies have shown promising results in understanding the role of transposable elements in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Chiappinelli, Katherine B — George Washington University
- Study coordinator: Chiappinelli, Katherine B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.